SOURCE: The Bedford Report

The Bedford Report

September 06, 2011 08:16 ET

Late-Stage Products From BioSante and Keryx Gaining Momentum

The Bedford Report Provides Equity Research on BioSante & Keryx Biopharmaceuticals

NEW YORK, NY--(Marketwire - Sep 6, 2011) - The importance of maintaining a steady pipeline of drugs to market is having varied effects on the biotechnology industry. Analysis by the professional services firm BDO argues that larger Pharmaceutical firms are increasing reliance on biotech companies to fill its pipeline, which has been a net positive for small biotech companies. The Bedford Report examines the outlook for companies in the biotechnology industry and provides investment research on BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) and Keryx Biopharmaceuticals, Inc. (NASDAQ: KERX). Access to the full company reports can be found at:

While the positive fundamentals are there, last month biotech stocks suffered from what MarketWatch's Val Brickates Kennedy calls the "Dendreon Effect." The article reports that biotech companies whose stocks have taken heavy hits include those that are at early stages of marketing new treatments.

"Pretty much every company that had just launched a product or was about to launch a product got crushed," Leerink Swann analyst Howard Liang explains.

The Bedford Report releases market research on the Biotechnology Industry so investors can stay ahead of the crowd and make the best investment decisions to maximize their returns. Take a few minutes to register with us free at and get exclusive access to our numerous analyst reports and industry newsletters.

BioSante is currently running three late-stage clinical trials of LibiGel, a female sexual dysfunction treatment. The company plans to file a new marketing application in early 2012. In June, BioSante said it had stopped enrolling patients in a safety trial because a data analysis indicated a 90-percent chance the drug would meet its goal.

Keryx Biopharmaceuticals said last week that an independent monitoring board recommended that its late-stage study of a potential colorectal cancer treatment continue as planned until it is completed.

The Bedford Report provides Market Research focused on equities that offer growth opportunities, value, and strong potential return. We strive to provide the most up-to-date market activities. We constantly create research reports and newsletters for our members. The Bedford Report has not been compensated by any of the above-mentioned publicly traded companies. The Bedford Report is compensated by other third party organizations for advertising services. We act as an independent research portal and are aware that all investment entails inherent risks. Please view the full disclaimer at

Contact Information